company background image
TELA

TELA Bio NasdaqGM:TELA Stock Report

Last Price

US$8.38

Market Cap

US$122.0m

7D

-1.2%

1Y

-36.8%

Updated

21 May, 2022

Data

Company Financials +
TELA fundamental analysis
Snowflake Score
Valuation0/6
Future Growth2/6
Past Performance0/6
Financial Health3/6
Dividends0/6

TELA Stock Overview

TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient’s anatomy.

TELA Bio Competitors

Price History & Performance

Summary of all time highs, changes and price drops for TELA Bio
Historical stock prices
Current Share PriceUS$8.38
52 Week HighUS$16.53
52 Week LowUS$7.23
Beta1.57
1 Month Change-12.80%
3 Month Change-28.98%
1 Year Change-36.75%
3 Year Changen/a
5 Year Changen/a
Change since IPO-37.23%

Recent News & Updates

May 12
Is TELA Bio (NASDAQ:TELA) Using Debt Sensibly?

Is TELA Bio (NASDAQ:TELA) Using Debt Sensibly?

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...

Shareholder Returns

TELAUS Medical EquipmentUS Market
7D-1.2%0.5%-2.7%
1Y-36.8%-16.2%-12.9%

Return vs Industry: TELA underperformed the US Medical Equipment industry which returned -16.2% over the past year.

Return vs Market: TELA underperformed the US Market which returned -12.9% over the past year.

Price Volatility

Is TELA's price volatile compared to industry and market?
TELA volatility
TELA Average Weekly Movement6.2%
Medical Equipment Industry Average Movement10.6%
Market Average Movement7.8%
10% most volatile stocks in US Market16.8%
10% least volatile stocks in US Market2.9%

Stable Share Price: TELA is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 6% a week.

Volatility Over Time: TELA's weekly volatility (6%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2012123Antony Koblishhttps://www.telabio.com

TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient’s anatomy. It provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be used in laparoscopic and robotic-assisted hernia surgical repairs. The company markets its products through a single direct sales force, principally in the United States.

TELA Bio Fundamentals Summary

How do TELA Bio's earnings and revenue compare to its market cap?
TELA fundamental statistics
Market CapUS$121.99m
Earnings (TTM)-US$36.00m
Revenue (TTM)US$31.82m

3.8x

P/S Ratio

-3.4x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
TELA income statement (TTM)
RevenueUS$31.82m
Cost of RevenueUS$11.17m
Gross ProfitUS$20.65m
Other ExpensesUS$56.65m
Earnings-US$36.00m

Last Reported Earnings

Mar 31, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-2.47
Gross Margin64.91%
Net Profit Margin-113.15%
Debt/Equity Ratio315.5%

How did TELA perform over the long term?

See historical performance and comparison

Valuation

Is TELA Bio undervalued compared to its fair value and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • PE vs Industry

  • PE vs Market

  • PEG Ratio

  • PB vs Industry


12.15x

Price to Book (PB) ratio

Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate TELA's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate TELA's fair value for valuation analysis.


Price To Earnings Ratio

PE vs Industry: TELA is unprofitable, so we can't compare its PE Ratio to the US Medical Equipment industry average.

PE vs Market: TELA is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate TELA's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: TELA is overvalued based on its PB Ratio (12.2x) compared to the US Medical Equipment industry average (2.4x).


Future Growth

How is TELA Bio forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?

Future Growth Score

2/6

Future Growth Score 2/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


18.7%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: TELA is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: TELA is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: TELA is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: TELA's revenue (25.9% per year) is forecast to grow faster than the US market (7.8% per year).

High Growth Revenue: TELA's revenue (25.9% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if TELA's Return on Equity is forecast to be high in 3 years time


Past Performance

How has TELA Bio performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


-4.3%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: TELA is currently unprofitable.

Growing Profit Margin: TELA is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: TELA is unprofitable, and losses have increased over the past 5 years at a rate of 4.3% per year.

Accelerating Growth: Unable to compare TELA's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: TELA is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (14.5%).


Return on Equity

High ROE: TELA has a negative Return on Equity (-358.66%), as it is currently unprofitable.


Financial Health

How is TELA Bio's financial position?

Financial Health Score

3/6

Financial Health Score 3/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: TELA's short term assets ($50.3M) exceed its short term liabilities ($12.3M).

Long Term Liabilities: TELA's short term assets ($50.3M) exceed its long term liabilities ($33.0M).


Debt to Equity History and Analysis

Debt Level: TELA has more cash than its total debt.

Reducing Debt: Insufficient data to determine if TELA's debt to equity ratio has reduced over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: TELA has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: TELA has less than a year of cash runway if free cash flow continues to reduce at historical rates of 9.7% each year


Dividend

What is TELA Bio current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate TELA's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate TELA's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if TELA's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if TELA's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as TELA has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

1.0yrs

Average management tenure


CEO

Antony Koblish (55 yo)

10.08yrs

Tenure

US$2,107,685

Compensation

Mr. Antony Koblish is an Operating Partner of 1315 Capital LLC. Mr. Koblish serves as the President, Director and Chief Executive Officer of TELA Bio, Inc. since April 2012, which he co-founded in April 20...


CEO Compensation Analysis

Compensation vs Market: Antony's total compensation ($USD2.11M) is above average for companies of similar size in the US market ($USD771.12K).

Compensation vs Earnings: Antony's compensation has increased whilst the company is unprofitable.


Leadership Team

Experienced Management: TELA's management team is not considered experienced ( 1 years average tenure), which suggests a new team.


Board Members

Experienced Board: TELA's board of directors are not considered experienced ( 2.5 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

TELA Bio, Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: TELA Bio, Inc.
  • Ticker: TELA
  • Exchange: NasdaqGM
  • Founded: 2012
  • Industry: Health Care Supplies
  • Sector: Healthcare
  • Implied Market Cap: US$121.992m
  • Shares outstanding: 14.56m
  • Website: https://www.telabio.com

Number of Employees


Location

  • TELA Bio, Inc.
  • 1 Great Valley Parkway
  • Suite 24
  • Malvern
  • Pennsylvania
  • 19355
  • United States

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/05/21 00:00
End of Day Share Price2022/05/20 00:00
Earnings2022/03/31
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.